A phase II, open-label, randomized, multi-center study comparing the efficacy and safety of Sacituzumab govitecan versus investigator’s choice in patients with cancer of unknown primary (CUP) who are relapsed after or refractory to platinum-based chemotherapy
Sponsor: Universitaetsklinikum Heidelberg AöR
Phase: 2
Disease: Unfavorable cancer of unknown primary, Adenocarcinoma of unknown primary, Squamous cell carcinoma of unknown primary, Poorly differentiated carcinoma of unknown primary
EU trial number: 2025-523055-55-00
Population: Adults with histologically confirmed unfavorable, poor-prognosis cancer of unknown primary, measurable disease, ECOG performance status 0–2, and relapse or progression after at least three cycles of platinum-based chemotherapy.
Register Investigator Interest
Interested in offering this trial to suitable patients?